Alissa Crispino, Senior Vice President, Advocacy Communications and Policy at American Cancer Society Cancer Action Network, shared a post on LinkedIn:
“Clinical trial enrollment is low – to the tune of 7% – not because people are afraid or disinterested, but because of a system that continues to make finding an appropriate trial a Herculean task.
Inspiring remarks from Assal Sayas – Sr. Advisor, Biden Cancer Moonshot and cancer patient – at the American Cancer Society Cancer Action Network (ACS CAN) meeting Improving the Cancer Clinical Trial Matching Ecosystem.
ACS CAN, led by my colleague Mark Fleury, is doing important work so patients and their families have a better opportunity to access potentially lifesaving, innovative cancer therapies in clinical trials.”
